HOME
SEARCH
RSS FEED
SUBSCRIBE
Novel Dopamine D2 Receptor Antagonists and Methods of Their Use
Case ID:
TAB-2813
Web Published:
12/6/2022
Description:
Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA approved antipsychotic agents are antagonists of this receptor. Unfortunately, most agents that act as antagonists of D2 DAR are problematic, either they are less efficacious than desired or cause multiple adverse effects. Thus, it is desirable to develop a class of novel therapeutic agents with high selectivity for the D2 DAR. This invention describes dihydrobenzo[b,f][1,4]thiazepine-8-carboxamide compounds, methods of making these compounds, methods of characterizing their in vitro activity, demonstration of in vivo activity in animals, as well as methods of using these compounds to treat central nervous system (CNS) related disorders.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Novel_Dopamine_D2_Receptor_Antagonis ts_and_Methods_of_Their_Use
Category(s):
Collaboration
Psychiatry/Mental Health
Neurology
Research Materials
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Susan Ano
Technology Development Coordinator
NIH Technology Transfer
301-435-5515
susan.ano@nih.gov
Inventors:
Juan Marugan
Jingbo Xiao
Marc Ferrer-Alegre
Noel Southall
R Benjamin Free
David Sibley
Keywords:
Agents
ANTAGONISTS
ANTIPSYCHOTIC
D2
Dopamine
Human
NB2BXX
NB2XXX
Potential
RECEPTOR
SELECTIVE
VEXXXX
VNXXXX
WIXXXX
WKXXXX
YBXXXX
YCXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum